论文部分内容阅读
目的观察评价多西他赛联合吉西他滨治疗转移性乳腺癌的近期疗效及安全性。方法选择有可评价病灶的转移性乳腺癌患者36例,以多西他赛75mg/m2,吉西他滨1.0g/m2iv·d1,8,方案治疗4～6周期后进行疗效及毒副反应分析。结果 36例中,CR1例(2.8%),PR19例(52.8%),总有效率(CR+PR)为55.6%,此外SD9例(25.0%),PD7例(19.4%)。中位随访时间7个月,中位无进展生存期为7.68个月,主要毒副反应为骨髓抑制、皮疹、恶心及呕吐等,仅有1例出现严重骨髓抑制,且经处理后可继续化疗。结论多西他赛联合吉西他滨在治疗晚期转移性乳腺癌方面有较好疗效,不良反应可耐受,是一种患者可接受的治疗方法。
Objective To observe and evaluate the short-term efficacy and safety of docetaxel plus gemcitabine in the treatment of metastatic breast cancer. Methods Thirty-six patients with metastatic breast cancer with evaluable lesions were treated with docetaxel 75mg / m2 and gemcitabine 1.0g / m2iv · d1,8 for 4 ~ 6 cycles after treatment. The curative effect and toxicity were analyzed. Results The total effective rate (CR + PR) was 55.6% in CR1 cases (2.8%), PR19 cases (52.8%) and SD7 cases (25.0%) and PD7 cases (19.4%) in 36 cases. The median follow-up time was 7 months, with a median progression-free survival of 7.68 months. The main adverse reactions were myelosuppression, rash, nausea and vomiting. Only 1 patient had severe myelosuppression and continued to undergo chemotherapy after treatment . Conclusion Docetaxel combined with gemcitabine in the treatment of advanced metastatic breast cancer has a good effect, tolerable adverse reactions, is a patient acceptable treatment.